BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 23298851)

  • 1. Concurrent treatment with gonadotropin-releasing hormone agonists for chemotherapy-induced ovarian damage in premenopausal women with breast cancer: a meta-analysis of randomized controlled trials.
    Yang B; Shi W; Yang J; Liu H; Zhao H; Li X; Jiao S
    Breast; 2013 Apr; 22(2):150-157. PubMed ID: 23298851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in premenopausal women.
    Chen H; Xiao L; Li J; Cui L; Huang W
    Cochrane Database Syst Rev; 2019 Mar; 3(3):CD008018. PubMed ID: 30827035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant gonadotropin-releasing hormone analogues for the prevention of chemotherapy induced premature ovarian failure in premenopausal women.
    Chen H; Li J; Cui T; Hu L
    Cochrane Database Syst Rev; 2011 Nov; (11):CD008018. PubMed ID: 22071842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utility of gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage in premenopausal women with breast cancer: a systematic review and meta-analysis.
    Shen YW; Zhang XM; Lv M; Chen L; Qin TJ; Wang F; Yang J; Liu PJ; Yang J
    Onco Targets Ther; 2015; 8():3349-59. PubMed ID: 26622183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gonadotropin-releasing hormone agonists for ovarian protection during cancer chemotherapy: systematic review and meta-analysis.
    Senra JC; Roque M; Talim MCT; Reis FM; Tavares RLC
    Ultrasound Obstet Gynecol; 2018 Jan; 51(1):77-86. PubMed ID: 29055060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in cancer women: systematic review and meta-analysis of randomized trials.
    Del Mastro L; Ceppi M; Poggio F; Bighin C; Peccatori F; Demeestere I; Levaggi A; Giraudi S; Lambertini M; D'Alonzo A; Canavese G; Pronzato P; Bruzzi P
    Cancer Treat Rev; 2014 Jun; 40(5):675-83. PubMed ID: 24360817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ovarian suppression using luteinizing hormone-releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: a meta-analysis of randomized studies.
    Lambertini M; Ceppi M; Poggio F; Peccatori FA; Azim HA; Ugolini D; Pronzato P; Loibl S; Moore HC; Partridge AH; Bruzzi P; Del Mastro L
    Ann Oncol; 2015 Dec; 26(12):2408-19. PubMed ID: 26347105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gonadotropin-Releasing Hormone Agonists for Ovarian Function Preservation in Premenopausal Women Undergoing Chemotherapy for Early-Stage Breast Cancer: A Systematic Review and Meta-analysis.
    Munhoz RR; Pereira AA; Sasse AD; Hoff PM; Traina TA; Hudis CA; Marques RJ
    JAMA Oncol; 2016 Jan; 2(1):65-73. PubMed ID: 26426573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protection of ovarian function by GnRH agonists during chemotherapy: a meta-analysis.
    Sun X; Dongol S; Jiang J; Kong B
    Int J Oncol; 2014 Apr; 44(4):1335-40. PubMed ID: 24535045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protecting Ovaries During Chemotherapy Through Gonad Suppression: A Systematic Review and Meta-analysis.
    Elgindy E; Sibai H; Abdelghani A; Mostafa M
    Obstet Gynecol; 2015 Jul; 126(1):187-95. PubMed ID: 26241272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gonadotropin-releasing hormone analog cotreatment for preservation of ovarian function during gonadotoxic chemotherapy: a systematic review and meta-analysis.
    Bedaiwy MA; Abou-Setta AM; Desai N; Hurd W; Starks D; El-Nashar SA; Al-Inany HG; Falcone T
    Fertil Steril; 2011 Mar; 95(3):906-14.e1-4. PubMed ID: 21145541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gonadotropin-Releasing Hormone Agonists During Chemotherapy for Preservation of Ovarian Function and Fertility in Premenopausal Patients With Early Breast Cancer: A Systematic Review and Meta-Analysis of Individual Patient-Level Data.
    Lambertini M; Moore HCF; Leonard RCF; Loibl S; Munster P; Bruzzone M; Boni L; Unger JM; Anderson RA; Mehta K; Minton S; Poggio F; Albain KS; Adamson DJA; Gerber B; Cripps A; Bertelli G; Seiler S; Ceppi M; Partridge AH; Del Mastro L
    J Clin Oncol; 2018 Jul; 36(19):1981-1990. PubMed ID: 29718793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gonadotropin-releasing hormone agonists for the preservation of ovarian function among women with breast cancer who did not use tamoxifen after chemotherapy: a systematic review and meta-analysis.
    Vitek WS; Shayne M; Hoeger K; Han Y; Messing S; Fung C
    Fertil Steril; 2014 Sep; 102(3):808-815.e1. PubMed ID: 25044080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gonadotropin-releasing hormone agonists for ovarian protection during breast cancer chemotherapy: a systematic review and meta-analysis.
    Li ZY; Dong YL; Cao XZ; Ren SS; Zhang Z
    Menopause; 2022 Sep; 29(9):1093-1100. PubMed ID: 35917530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncologic Safety of Gonadotropin-Releasing Hormone Agonist for Ovarian Function Protection During Breast Cancer Chemotherapy.
    Kim HJ; Lee MH; Lee JE; Park S; Lee ES; Kang YJ; Shin HN; Kim SI; Lee JH; Im SA; Ahn SH; Lee KS; Sohn J; Kim S; Nam SJ; Han W
    Clin Breast Cancer; 2018 Oct; 18(5):e1165-e1172. PubMed ID: 29843988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study.
    Badawy A; Elnashar A; El-Ashry M; Shahat M
    Fertil Steril; 2009 Mar; 91(3):694-7. PubMed ID: 18675959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ovarian function preservation with GnRH agonist in young breast cancer patients: does it impede the effect of adjuvant chemotherapy?
    Kim J; Kim M; Lee JH; Lee H; Lee SK; Bae SY; Jun SY; Kil WH; Lee JE; Kim SW; Nam SJ
    Breast; 2014 Oct; 23(5):670-5. PubMed ID: 25088482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gonadotropin-Releasing Hormone Analog Cotreatment for the Preservation of Ovarian Function during Gonadotoxic Chemotherapy for Breast Cancer: A Meta-Analysis.
    Wang C; Chen M; Fu F; Huang M
    PLoS One; 2013; 8(6):e66360. PubMed ID: 23805216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial.
    Del Mastro L; Boni L; Michelotti A; Gamucci T; Olmeo N; Gori S; Giordano M; Garrone O; Pronzato P; Bighin C; Levaggi A; Giraudi S; Cresti N; Magnolfi E; Scotto T; Vecchio C; Venturini M
    JAMA; 2011 Jul; 306(3):269-76. PubMed ID: 21771987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preservation of gonadal function in women undergoing chemotherapy: a systematic review and meta-analysis of the potential role for gonadotropin-releasing hormone agonists.
    Hickman LC; Llarena NC; Valentine LN; Liu X; Falcone T
    J Assist Reprod Genet; 2018 Apr; 35(4):571-581. PubMed ID: 29470701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.